Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma (NCT03543969)
Pilot Study of Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
🩺 Plain-English Summary (8th-Grade Level)
This pilot early phase I trial studies how well encorafenib, binimetinib, and nivolumab work in treating patients with BRAF mutant stage IIIC-IV melanoma. Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with nivolumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving encorafenib, binimetinib, and nivolumab may kill more tumor cells.
Who can join: Review the eligibility criteria below.
Location: H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Melanoma (Skin)
- High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma — Birmingham, Alabama
- A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma — Toronto, Ontario
- Zr89 + PET Companion Trial — Philadelphia, Pennsylvania
- Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma — Orange, California
- A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors — La Jolla, California
Explore by condition: All Melanoma (Skin) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.